Paul A Mahon, a vice president at United Therapeutics Corp ($UTHR), reported an open-market sale of 2,615 shares on October 15, 2026. The shares sold at $545.6873 each, for a total of $1,426,972.29, according to a Form 4 filed with the SEC on October 16 — one day after the transaction. The filing listed 45,891 shares owned after the sale.
That trade was one of six open-market sale line items Mahon reported on October 15. Combined, the six transactions covered 8,300 shares for a total of $4,517,708.96, at per-share prices ranging from $541.6421 to $546.5608. All six were filed on October 16. The smallest line item was 268 shares at $541.6421 for $145,160.08, and the largest was the 2,615-share trade at $1,426,972.29. Mahon's reported October 15 prices placed the 2,615-share sale near the top of that day's range.
The October 15 filing extended a run of reported insider sales at United Therapeutics. CEO Martine Rothblatt reported open-market sales on September 24, October 9, October 12, October 13, and October 14. Across those five trading days, her Form 4 filings covered 44,780 shares for a combined $23,741,683.51.
Rothblatt's daily totals, by transaction date, were:
- September 24: 9,500 shares, $4,498,752.61
- October 9: 7,740 shares, $4,221,208.31
- October 12: 9,500 shares, $5,231,666.41
- October 13: 9,500 shares, $5,182,414.18
- October 14: 8,540 shares, $4,607,642.00
Combined with Mahon's October 15 sales, the database showed 58 reported $UTHR insider transactions across the six dates from September 24 through October 15, all of them sales, totaling $28,259,392.48. No open-market purchases appeared in that window.
The reported per-share prices differed across the stretch. Rothblatt's September 24 sales were reported at prices between $469.7352 and $480.33, while the mid-October sales from both Rothblatt and Mahon were reported at prices between $526.07 and $554.4568. Rothblatt's September 24 sales were filed on September 25, one day after the trade. Her October 12, October 13, and October 14 sales were each filed one day after the trade date, while her October 9 sales were filed on October 13, a four-day lag.
United Therapeutics, a biotechnology company classified in the Biotechnology sector and industry, with a market capitalization of roughly $23.2 billion, has also appeared in congressional STOCK Act disclosures. Representative Michael T. McCaul reported $UTHR transactions as recently as October 27, 2025, with that sale carrying a disclosed-range midpoint of $15,001. In 2025, McCaul's $UTHR filings also included a sale on August 22, a purchase on August 7, and a sale on June 27. His $UTHR disclosure history in the database extends back to May 2021, spanning both purchases and sales. Representative Lisa Mcclain reported $UTHR purchases and sales in late October 2025, each with a disclosed-range midpoint of $1,001, and she also reported a $UTHR purchase in June 2025. Congressional dollar figures are midpoint estimates of bracketed disclosure ranges. Those congressional filings predate the October 2026 insider sales by roughly a year.